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Abstract
Background: Dysferlinopathies are caused by mutations in the dysferlin gene (DYSF). Diagnosis is complex due to the high
clinical variability of the disease and because dysferlin expression in the muscle biopsy may be secondarily reduced due to a
primary defect in some other gene. Dysferlin is also expressed in peripheral blood monocytes (PBM). Studying dysferlin in
monocytes is used for the diagnosis of dysferlin myopathies. The aim of the study was to determine whether dysferlin
expression in PBM correlates with that in skeletal muscle.
Methodology/Principal Findings: Using western-blot (WB) we quantified dysferlin expression in PBM from 21 pathological
controls with other myopathies in whom mutations in DYSF were excluded and from 17 patients who had dysferlinopathy
and two mutations in DYSF. Results were compared with protein expression in muscle by WB and immunohistochemistry
(IH). We found a good correlation between skeletal muscle and monocytes using WB. However, IH results were misleading
because abnormal expression of dysferlin was also observed in 13/21 pathological controls.
Conclusions/Significance: The analysis of dysferlin protein expression in PBM is helpful when: 1) the skeletal muscle IH
pattern is abnormal or 2) when muscle WB can not be performed either because muscle sample is lacking or
insufficient or because the muscle biopsy is taken from a muscle at an end-stage and it mainly consists of fat and
fibrotic tissue.
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Introduction
Dysferlinopathy is a type of muscular dystrophy characterized
by mutations in the DYSF gene [1,2]. It has a wide phenotypic
variability that includes distal forms, such as Miyoshi myopathy
(MM) and myopathy with onset in the distal anterior compartment
of the legs (DACM), a proximal form known as limb girdle
muscular dystrophy 2B (LGMD2B), and hyperCKemia
[3,4,5,6,7,8,9]. A congenital form and an early-onset form have
also been described [10]. In spite of the clinical variability, it has
been observed that muscle MRI shows that both distal and
proximal muscles are impaired from the onset of the disease in all
phenotypes [11]. As well as in skeletal muscle, dysferlin is
expressed in peripheral blood CD14
+ monocytes (PBM), as
reported in a series of 12 patients with MM or LGMD2B [12].
The findings from this latter study suggested that studying the
expression of dysferlin protein in these more accessible cells could
be a reliable method to diagnose dysferlinopathies and a valid
alternative to muscle biopsy. However, the expression of dysferlin
in monocytes was not compared with that in skeletal muscle. Wein
et al performed a flow cytometry study in a series of 6 patients with
dysferlin myopathy and found that dysferlin expression in PBM
differed between patients and controls, although the protocol
would not allow quantification of dysferlin using the antibody
NCL-Hamlet [13]. Furthermore, the authors did not compare the
expression of dysferlin between blood and muscle. The present
study was performed to assess whether there is a correlation
between the expression of dysferlin in skeletal muscle and that in
PBM. We analysed a large series of genetically characterized
patients comparing the expression of dysferlin in skeletal muscle by
immunohistochemistry (IH) and western blot (WB) with that in
PBM.
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Dysferlin protein is expressed as a double band in PBM
WB analysis showed dysferlin was expressed as a double band in
PBM. The molecular weight of the upper band corresponded to the
single band expressed in skeletal muscle (234 kDa) and the lower
band was approximately 8–10 kDa smaller. When monocytes were
transfected with dysferlin siRNAs, the intensity of the two bands
decreased significantly. Control siRNAs (siMYOF and non-target
siRNA)didnot affecttheproteinlevelsofthe doublet (Figure 1A). In
immunoprecipitation studies using both F4 and H7 antibodies
(Figure 1B) the doublet from PBM was pulled down (Figure 1C).
When a control antibody against b-amyloid was used we observed
the dysferlin doublet only in the non-bound fraction (Figure 1C).
These results indicate that both bands correspond to dysferlin
protein and support using both of them to quantify dysferlin in
Figure 1. Characterization of the double band corresponding to dysferlin observed in CD14+ PBM by WB. A) Dysferlin siRNA efficiently
reduced both dysferlin bands in PBM. Representative WB of monocytes from a healthy donor treated with siRNA showed that siDYSF efficiently
reduced the two bands corresponding to dysferlin. On the right, quantification of WB from silenced monocyte samples, corresponding to four
independent experiments, showed that when dysferlin was knocked down, levels diminished from 100% in Control (C) and 104.2611.3% in siMYOF
to 58.4614.8% with siDYSF1 (p,0.05) and 72.269.8% with siDYSF2 (p,0.05), error bars indicate standard desviation. B) Schematic overview of the
dysferlin protein and the epitopes recognized by F4, H7 and Hamlet antibodies. The three affinity binders together cover the complete dysferlin
protein sequence. C) Both F4 and H7 antibodies can immunoprecipitate the dysferlin doublet from PBM. Bound (B) and non-bound (NB) fractions
were analyzed by WB for dysferlin. The arrow denotes the dysferlin doublet observed in the bound fraction using F4 and H7 and in the non-bound
fraction using an antibody against b-amyloid.
doi:10.1371/journal.pone.0029061.g001
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whom the monocytes test was performed both bands were absent.
Mutation analysis of DYSF
We found two mutations in all 17 patients (Table 1). In order to
rule out the presence of two mutations in the same allele of DYSF,
parents of patients P_1, P_2, P_4, P_14, P_15 P_16, P_17 (table 1)
were analyzed and one of the familial mutations was found in each
one. In P_6, P_9, P_11 and P_12 (Table 1) only one of the two
mutations was found in their sons/daughters. In the remaining 6
patients (P_3, P_5, P_7, P_8, P_10 and P_13) (Table 1), DNA/
RNA sample from relatives was not available [3].
The expression of dysferlin in monocytes correlated with
that in skeletal muscle
In 21 cases with normal expression of dysferlin in PBM
(114.3617.8%), skeletal muscle WB was also normal (105616.3%)
(Figure 2A and Table 2).
We performed skeletal muscle WB in 17 dysferlinopathy
patients and we found that dysferlin expression was 1.164.3%.
Similar dysferlin levels of expression were found in PBM
(0.160.2%) (Figure 2B and Table 1). A WB of skeletal muscle
and PBMs from 2 patients and 2 controls all loaded in the same gel
was performed to confirm that primary deficiencies of dysferlin
can be easily detected in PBMs (Figure S1).
Patients with abnormal dysferlin staining by IH showed normal
levels of the protein by WB both in skeletal muscle and PBM
(Figure 2C)(C_1 in Table 2).
We measured the expression of dysferlin in PBM by WB in the
two previously reported symptomatic carriers [3]. The results were
37.963% in monocytes and 36.3612.2% in muscle (Figure 2D).
An X-Y plot was performed to confirm the parallelism between
dysferlin expression in PBM and in skeletal muscle (Figure 3).
We found absence of dysferlin staining in 11/17 patients with
abnormal dysferlin expression in PBM (Figure 4B). The remaining
6 patients had some degree of dysferlin expression in muscle. Two
Table 1. Summary of dysferlin myopathy patients: Correlation with protein expression in PBM, skeletal muscle and mutations.
Patient Sex Age Phenotype
PBM
WB (%)
Muscle
WB (%) Muscle IH
Nucleotide change
DYSF gene Protein change
P_1 M 31 MM 0 0 Sarcoplasm
granular pattern
c.5194G.T
c.5999G.A
p.Glu1732X
p.Arg2000Gln
P_2 M MM 0 0 Absent c.1555G.A
c.1555G.A
p.Gly519Arg
p.Gly519Arg
P_3 M 37 MM 0 0 Absent c.5159delG
c.5159delG
p.Arg1720LeufsX2
p.Arg1720LeufsX2
P_4 M 26 LGMD2B 0 0 Absent c.5509G.A
c.5903G.A
p.Asp1837Asn
p.Trp1968X
P_5 F 27 LGMD2B 0 0.2 Absent c.5979dupA
c.5979dupA
p.Glu1994ArgfsX3
p.Glu1994ArgfsX3
P_6 F 38 LGMD2B 0 0 Absent c.154T.C
c.701G.A
p.Trp52Arg
p.Gly234Glu
P_7 M 30 LGMD2B 0 0 Sarcoplasm
granular pattern
c.2779delG
c. 4410+13T.G
p.Ala927LeufsX21
P_8 M 36 LGMD2B 0.9 1.5 Patchy sarcolemmal
pattern
c.2055+1G.A
c.3805G.T
p.Glu1269X
P_9 F 49 LGMD2B 0 0 Absent c.4354C.A
c.4354C.A
p.Pro1452Thr
p.Pro1452Thr
P_10 F 63 LGMD2B 0 0 ABSENT c.5525+3A.G
c.5525+3A.G
P_11 F 44 LGMD2B 0 0 Absent c.5159delG
c.5979dupA
p.Arg1720LeufsX2
p.Glu1994ArgfsX3
P_12 F 73 LGMD2B 0 0 Absent c.2875C.T
c.2875C.T
p.Arg959Trp
p.Arg959Trp
P_13 M MM 0 0 Patchy sarcolemmal
pattern
c.4003G.A
c.4003G.A
p.Glu1335Lys
p.Glu1335Lys
P_14 F 28 DACM 0 0 Absent c.5594delG
c.5594delG
p.Gly1865AlafsX 101
p.Gly1865AlafsX 101
P_15 F 29 MM 0 18 Patchy sarcolemmal
pattern
c.5979dupA
c.9124C.T
p.Glu1994ArgfsX3
p.Arg2042Cys
P_16 M 17 LGMD2B 0 0 Sarcoplasm
granular pattern
c.4882G.A
c.4882G.A
p.Gly1628Arg
p.Gly1628Arg
P_17 M 5 LGMD2B 0.2 0 Absent c.2779delG
c.2779delG
p.Ala927LeufsX21
p.Ala927LeufsX21
M- male; F- female; MM: Miyoshi myopathy; LGMD2B: limb girdle muscular dystrophy; DACM: Distal anterior compartment myopathy.
The mutations of patients P_1, P_2, P_4, P_5, P_6, P_10, P_13, P_14 [12,17], P_15 [8] and P_17 [26] have been previously described. The intronic mutation, c.
4410+13T.G, of P_7 has been previously described in the Leyden Muscular Dystrophy web page (www.dmd.nl) (Accession number used NM_003494.2).
doi:10.1371/journal.pone.0029061.t001
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scattered fibres in 3/6 (P_1, P_7, P_16) (Figure 4D); and ii)
markedly reduced but unequivocal patchy sarcolemmal expression
in 3/6 (P_8, P_13 and P15) (Figure 4F). Analysis of the PBM WB
in these 6 patients showed 0.160.3% of dysferlin expression
compared to 060% in the 11 patients with absent dysferlin
immunostaining. We did not see any association with the type of
mutation or its location within DYSF either in these 6 patients with
residual amounts of dysferlin in the muscle biopsy or the 11
patients with absence of dysferlin (Table 1). In 21 muscle biopsies
from patients with normal dysferlin expression in PBM we found
different dysferlin staining patterns, similar to those previously
described [14]: Dysferlin expression was normal in the sarcolem-
ma in eight patients (C_5, C_6, C_7, C_10, C_11, C_12, C_17,
C_20) (Figure 4A). Of the other 13, four showed a general
reduction of a continuous staining (not patchy) of the sarcolemma
(C_8, C_9, C_19, C_21) (Figure 4C), three had reduced staining
in the sarcolemma but increased in the cytoplasm of all muscle
fibers (C_1 C_16, C_18) (Figure 4G), and six had increased signal
in the cytoplasm of only some fibres with normal expression in the
sarcolemma (P_2, P_3, P_4, P_13, P_14, P_15 (Figure 4H and
Table 2).
Discussion
Our study showed a reproducible relationship between dysferlin
expression in skeletal muscle and in PBM by WB analysis. Analysis
of 17 dysferlinopathy patients with two pathogenic mutations in
the gene DYSF and 21 patients with other neuromuscular diseases
confirmed normal levels of dysferlin in all the pathological controls
and abnormal dysferlin (severe reduction or absence) in all
dysferlinopathy patients, demonstrating a high sensitivity and
specificity for diagnosis of dysferlinopathy.
IH results, on the other hand, were misleading because dysferlin
expression was deficient both in patients with mutations in DYSF
and in patients with other myopathies. Most patients with DYSF
mutations showed absence of dysferlin in IH, but some showed
residual dysferlin expression. A large proportion of pathological
controls with other myopathies (13/21) showed abnormal patterns
of dysferlin expression using IH but their dysferlin expression in
skeletal muscle and PBM was normal according to WB.
Several authors have described different IH patterns of dysferlin
expression in muscle biopsies from patients with different
myopathies, but none of them compared this expression with that
found in PBM. The authors in the first of these studies found IH
patterns which were slightly different from those in our study.
However, they did not correlate their findings with muscle WB
[15]. In two later papers, the authors observed mismatching results
between WB and IH in muscle biopsies from different LGMD
[14,16]. In the paper by Tagawa et al the authors found defective
expression of dysferlin by IH, 19% of patients with LGMD and
50% of patients with other neuromuscular diseases, and
established four different patterns of dysferlin staining (normal,
negative, faint and abnormal cytoplasmic accumulation) The
authors concluded that other proteins are necessary for a normal
localization of dysferlin at the sarcolemma. In the paper by Lo et al
Figure 2. Correlation between dysferlin expression in skeletal muscle, detected by IH and WB, and WB of PBM. A) Healthy control with
normal expression of dysferlin in PBM: Dysferlin is expressed in the sarcolemma of muscle fibres. WB of skeletal muscle and PBM showed normal
levels of dysferlin. B) Dysferlinopathy patient (P_3): Dysferlin is absent in sarcolemma by IH, WB and in PBM. C) Patient with LGMD2A (C_1) showing
abnormal expression of dysferlin in skeletal muscle by IH but normal levels in skeletal muscle and PBM WB. D) Symptomatic carrier of one mutation in
DYSF: muscle IH and WB show reduced expression that was confirmed in PBM. HMZ: homozygous.
doi:10.1371/journal.pone.0029061.g002
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proportion of LGMD patients not LGMD2B (25 out of 76). They
grouped these patients in four categories according to IH pattern
of dysferlin expression in the muscle biopsy including: 1)
deficiency, 2) reduced membrane staining, 3) reduced membrane
staining with homogenously increased sarcoplasmic staining in all
fibers and 4) reduced membrane staining and variable sarcoplas-
mic staining in some fibers. To explain their results the authors
suggested that either the membrane damage is too excessive for
satellite cells to repair or that the proteins needed for dysferlin
function are defective in these patients. The results of both studies
matched well with those found in our study (Figure 4). In yet
another study, the authors found a patchy pattern of sarcolemmal
dysferlin in two patients with 59 donor site mutations, but these
mutations could not be related to a milder clinical phenotype [17].
In a more recent paper the authors described three patients with
a suspicion of dysferlinopathy who displayed abnormal skeletal
muscle IH (reduced or absent) and increased dysferlin protein by
WB.In two of the three patients, genetic analysis showed a non-
pathogenic change in one allele and no change in the second
allele. The third patient displayed one pathogenic mutation in one
allele and a non-pathogenic change in the second allele. WB in
PBM was performed in two of the three patients and dysferlin
expression was normal in both. The quantification method and the
WB, however, were not shown [18]. Together with our findings
these results indicate that normal dysferlin expression has not yet
been observed when two pathogenic mutations in the DYSF gene
are found.
Dysferlin interacts with other proteins to form a complex, such
as annexin-1 and 2 [19], calpain-3 [20,21], caveolin-3 [22],
AHNAK [23], affixin [24], dihydropyridine receptor [25], MG53
[26] and tubulin [27]. Disruption of proteins in the dysferlin
complex can affect the subcellular localization of dysferlin in the
absence of mutations in the gene DYSF and may explain the
abnormal immunohistochemical results described in the above-
mentioned studies [14,22,28,29,30]. For this reason it is important
to quantify dysferlin expression in skeletal muscle WB as well as by
IH. However, in some cases the amount of muscle biopsy is
insufficient to perform WB. It may also happen that in patients at
end stages of the disease the muscle biopsy may mainly consist of
fat and fibrotic tissue, also leading to inaccurate quantification
results of muscle proteins. To overcome these difficulties, here we
Table 2. Summary of patients with normal expression of dysferlin included in this study.
Patient Sex Age Phentoype
PBM
WB
(%)
Muscle
WB
(%)
Muscle
IH Gene Nucleotide change Protein change
C_1 M 19 LGMD2A 121.6 110.5 2 CAPN3 c.2362_2363delinsTCATCT
c.2362_2363delinsTCATCT
p.Arg788SerfsX14
p.Arg788SerfsX14
C_2 M 48 BMD 100 96 3 DYS c.1704+2T.A p.Cys569ValfsX18
C_3 M 73 POMPE 116.2 93.6 3 GAA c.1195_1G.A
c.1856G.A
IVS17
p.Ser619Asn
C_4 F 40 POMPE 125 118.7 3 GAA c.32_13T.G
c.236_246delCCACACAGTGC
IVS1-13 T.G
p.Pro79ArgfsX13
C_5 F 56 POMPE 110.5 100 N GAA c.32_13T.G
c.2600_2604delTGCTGinsA
IVS1-13 T.G;
p.Val1867GlufsX19
C_6 F 30 ANO5 100 100 N ANO5 c.191dupA
c.1627dupA
p.Asn64LysfsX15
p.Met543AsnfsX11
C_7 M 35 Mitochondrial myopathy 100 98.6 N
C_8 F 46 Nonaka 110.5 100 1 GNE c.934G.A
c.1519A.C
p.Gly312Arg
p.Thr507Pro
C_9* M 62 HyperCKs 140 105.2 1
C_10 F McArdle 100 100 N PYGM c.1979C.T
c.1760T.C
p.Ala660Asp
p.Leu587Pro
C_11 F 59 VCP 149.4 130.1 N VCP c.277C.T p.Arg93Cys
C_12 M 55 PM 100 77.5 N
C_13 F 57 PM 98.3 89.9 3
C_14* M 43 LGMD 100 99.5 3
C_15* M 46 LGMD 150 132.6 3
C_16* M 43 LGMD 100 100 2
C_17* F 29 HyperCKs 98.3 93.3 N
C_18* M 61 Myalgias hiperCKs 140 151.1 2
C_19* M 59 Muscular dystrophy 114.9 108 1
C_20* M 49 Calf atrophy 125.5 100 N
C_21* M 42 MM like 100 100 1
N-Normal; 1- reduced sarcolemma; 2- Reduced sarcolemma and increased sarcoplasm staining; 3- Variable sarcoplasm staining.
*Patients with DYSF gene analyzed and no mutations found.
M:male; F: female; LGMD: limb girdle muscle dystrophy; VCP: valosin containing protein; PM: polimyositis; MM: Miyoshi myopathy. HMZ: homozygous.
The mutation of pathological control C_X have been previously described [38].
doi:10.1371/journal.pone.0029061.t002
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interpret the reductions noted in the muscle biopsy by IH. Indeed,
when the clinical suspicion of dysferlinopathy is high, dysferlin in
PBM can be studied even before the muscle biopsy is taken. The
mean expression of dysferlin by skeletal muscle WB in our patients
was 1.164.3% and linked with that in monocytes. It is of note that
the authors of a very recent report showed that when the
expression of dysferlin in skeletal muscle analysed by WB was
lower than 20% it was due to mutations in the gene DYSF [31].
The authors, however, did not compare dysferlin expression in
PBM in the same patients, as we did in our study.
The analysis of dysferlin in PBM is very helpful to rule out a
dysferlinopathy when no muscle sample is available. However,
when available, the study of the muscle biopsy is very informative.
In fact, the presence of characteristic inflammatory infiltrates [32]
and sarcolemmal and interstitial amyloid deposits [33] can be
helpful to support the diagnosis of dysferlinopathy and to study the
pathogenesis of the disease.
The high parallelism between dysferlin expression in skeletal
muscle and PBM by WB found in our study has improved the
diagnostic approach in our routine practice, avoiding misleading
diagnoses when the IH pattern is abnormal. In the diagnostic work
up of a patient with proximal or distal weakness, we suggest to
investigate the presence of dysferlin by WB in PBM in
combination with the muscle biopsy prior to molecular analysis
of a large gene such as DYSF.
Materials and Methods
Subjects
Patients were recruited at our neuromuscular unit, a reference
center for dysferlin myopathy in Spain. The diagnosis of
dysferlinopathy and other muscular dystrophies included the
neurological examination and muscle MRI. Most cases also
included a muscle biopsy to guide genetic analysis regarding the
defective protein using IH and WB. PBM WB was carried out in 17
patients with two mutations in the DYSF gene and in 21 patients
with other neuromuscular diseases. Our clinical research ethics
committee approved this study (Reference number of our Ethics
Committee: 08/77/883). Informed consent was obtained from all
patients for muscle biopsy, blood samples and RNA/DNA analysis.
Isolation of PBM and immunoblot analysis
PBM-CD14 positive isolation was carried out in all subjects as
previously described [12]. WB from human monocyte samples was
performed using a mouse monoclonal antibody to dysferlin (NCL-
Hamlet, Novocastra, Newcastle, UK) and a mouse monoclonal
antibody to b-actin (Sigma-Aldrich Quimica, Madrid, Spain) as a
loading control. IRDyeH800 conjugate goat anti-mouse was used
as a secondary antibody (Li-cor, Lincoln, Nebraska, USA).
Fluorescent bands corresponding to dysferlin and b-actin were
acquired and analyzed using an Odyssey Infrared Imaging System
(Li-cor). To determine dysferlin expression we quantified the
double band observed in PBM. The control samples were used as
reference values and assigned 100% of dysferlin expression using
b-actin as a normalizer. The amount of dysferlin shows some
variation among different healthy individuals. We used several
healthy controls to perform the different dysferlin expression
determinations, since the same individual control sample was not
always available. When performing a WB we assign a value of
100% to a healthy individual that has no mutations in DYSF. For
this reason, in a given gel, an individual with a pathology other
that dysferlinopathy or in other healthy individuals the levels of
dysferlin may be slighty higher or lower than 100%. Dysferlin
expression in patient samples was quantified using the control
values to obtain the percentages of dysferlin expression/reduction.
Dysferlin knockdown
We performed an RNA inference experiment to confirm that
the double band present in PBM corresponded to dysferlin.
Human monocytes from healthy donors were isolated using the
EasySep Human Monocyte Enrichment kit (Stemcell Technolo-
gies, Sheffield, UK) following the manufacturer’s instructions.
230,000 monocytes/sample (100,000 monocytes/ml) were
transfected with siRNA/siPORT Amine (Ambion, Texas, USA)
at a concentration of 30 nM/5ml. siRNAs used were: siDYSF-1
target in exon 2 (s15788), siDYSF-2 target in exon 48 (s15790),
siMYOF (s25476) as a non-related gene and a negative control
(AM4611). Monocyte cultures were incubated with siRNAs for 6
days and dysferlin protein was analyzed by WB.
Immunoprecipitation
Freshly isolated PBM were lysed on ice in buffer composed of
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.15% CHAPS and 16
protease inhibitor cocktail. The lysates were spun down at
maximum speed, 4uC, 20 min. Protein A Sepharose CL-4B
(Amersham) was washed 36in lysis buffer and used to preclear the
homogenates for 1 h, at 4uC while shaking. Sepharose was
removed and antibody was added (50 mg Heavy Chain Antibody
(HCAb) fragment) and shaken o/n at 4uC. HCAb fragments F4
(amino acids 2–245) and H7 (amino acids 1666–1788) (both
Dysferlin specific) (Figure 2A and 3A) (non-specific control against
amyloid-b 34) were described previously [21,34]. The washed
Sepharose was then added, incubated while shaking for 2 h at
4uC. Bound and non-bound IP samples were separated on SDS-
page gels and blotted onto a nitrocellulose membrane. Primary
antibody (Hamlet) against amino acids 1999–2016, was incubated
o/n and secondary antibody for 1 h. Detections were performed
with an Odyssey scanner (Li-Cor).
Mutation analysis of DYSF
Mutation screening in the DYSF gene was performed in 25
patients, the seventeen with abnormal dysferlin by WB and eight
patients from the pathological control group with normal levels of
dysferlin protein in WB from muscle and monocytes and no final
Figure 3. Parallelism between dysferlin expression in PBM and
in skeletal muscle. Linear association between dysferlin expression in
skeletal muscle (X axis) and in PBM (Y axis) were observed (R
2=0.9766,
p,0.001). Black diamonds show dysferlin expression in pathological
controls and white diamonds show dysferlin expression in dysferlino-
pathy patients.
doi:10.1371/journal.pone.0029061.g003
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29061Figure 4. Dysferlin staining patterns in muscle biopsy from dysferlinopathy patients and from other muscle diseases. Muscle biopsies
from dysferlinopathy patients show three staining patterns: A) Normal dysferlin staining in a pathological control muscle (C_20 with calf atrophy in
Table 2). B) Total absence of dysferlin expression at sarcolemma and sarcoplasm (P_2 with Miyoshi myopathy in Table 1). C) reduced sarcolemmal
staining in all muscles (C_8 with Nonaka myopathy in Table 2). D) A sarcoplasm granular pattern in scattered fibers was observed in some
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using Ultraspec (Biotech Laboratories, Houston, USA) and
retrotranscribed with the oligo(dT) primer technique (Invitrogen,
Carsbad, USA). Amplification and direct sequencing of the entire
dysferlin cDNA was performed using 14 sets of oligonuclotide
primers covering the 55 exons, as previously described [35].
Skeletal muscle immunohistochemistry and immunoblot
We studied dysferlin expression in muscle in 38 biopsy samples.
Immunohistochemistry was performed as previously described
[36]. The slides were incubated overnight with a primary antibody
to human dysferlin (NCL-Hamlet) at a final concentration of
10 mg/ml. After a washing step, slides were incubated with a
secondary antibody for 1 hour at room temperature. Samples
were then mounted and directly examined using an Axioscop 2
plus photomicroscope equipped with epifluorescence optics and
bright field (Carl Zeiss, Munich, Germany). Lysates from the same
38 skeletal muscle biopsies were analyzed by WB as previously
described [3,37]. Briefly, frozen muscle samples were homoge-
nized with 19 volumes of treatment buffer containing 0.125 mol/L
Tris/HCL buffer pH 6.4, 10% glycerol, 4% SDS, 4 mol/L urea,
10% mercaptoethanol and 0.001% bromophenol blue and 30 ml
of samples were loaded in the gel (equivalent to 200 mg of non-
collagen protein). Immunoblots were performed as described
above for monocytes.
Supporting Information
Figure S1 Western blot of skeletal muscle and PBMs from 2
patients and 2 controls all loaded on the same gel using an
antibody to dysferlin (Hamlet).
(TIF)
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